They lack opioid activity but are potent stimulators of growth hormone (GH) release.

These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor.

Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1).

A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2).